• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Zura Bio Limited

    9/13/24 4:24:27 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ZURA alert in real time by email
    DEFA14A 1 tm2423789d2_defa14a.htm DEFA14A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.    )

     

    Filed by the Registrant     x

     

    Filed by a Party other than the Registrant     ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

    Zura Bio Limited

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required.

     

    ¨Fee paid previously with preliminary materials.

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

    GRAPHIC

    PROXY ZURA BIO LIMITED Annual General Meeting of Shareholders To be held on October 23, 2024 at 12:00 p.m. EDT This proxy is solicited by the Board of Directors The shareholder(s) named below, revoking all prior proxies, hereby appoint(s) Robert Lisicki, Verender Badial, and Kim Davis, or any of them, as proxies, each with the power to appoint his or her substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the Class A ordinary shares of Zura Bio Limited (the “Company”) that the shareholder(s) is/are entitled to vote at the Annual General Meeting of Shareholders (the “Annual Meeting”) to be held at 12:00 p.m. EDT on Wednesday, October 23, 2024 and any adjournment thereof. The Annual Meeting will be held virtually, and for purposes of the Second Amended and Restated Memorandum and Articles of Association of the Company, the physical place of the Annual Meeting shall be at the offices of Cooley LLP, located at 55 Hudson Yards, New York, New York 10001, United States of America. In order to attend the meeting virtually, you must register at https://web.viewproxy.com/zura/2024 by 11:59 p.m. EDT on Tuesday, October 22, 2024. On the day of the Annual Meeting, if you have properly registered, you may enter the meeting by clicking on the link provided and entering the password you received via email in your registration confirmations. Further instructions on how to attend and vote at the Annual Meeting are contained in the Proxy Statement in the Sections titled “Questions and Answers About These Proxy Materials and Voting” under the headings “How do I attend the Annual Meeting?” and “How do I vote?” This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors’ recommendations. (Continued and to be marked, dated, and signed on other side) • PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. • Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Annual Report and Proxy Statement are available at: https://web.viewproxy.com/ZURA/2024

    GRAPHIC

    DO NOT PRINT IN THIS AREA (Shareholder Name & Address Data) VIRTUAL CONTROL NUMBER INTERNET Vote Your Proxy on the Internet: Go to www.AALvote.com/ZURA Have your proxy card available when you access the above website. Follow the prompts to vote your shares. MAIL Vote Your Proxy by Mail: Mark, sign, and date your proxy card, then detach it and return it in the postage-paid envelope provided. Please mark your votes like this ց The Board of Directors recommends that you vote “FOR” each of the director nominees listed in Proposal 1, and “FOR” Proposals 2 and 3: Proposal 1. Election of Directors: To elect, by ordinary resolution, nine (9) nominees for director to the Company’s Board of Directors to hold office until the next annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal. Address Change/Comments: (If you noted any Address Changes and/or Comments above, please mark box.) տ (1) Neil Graham տ տ տ (2) Jennifer Jarrett տ տ տ (3) Sandeep Kulkarni տ տ տ (4) Robert Lisicki տ տ տ (5) Amit Munshi տ տ տ (6) Arnout Ploos van Amstel տ տ տ (7) Steve Schoch տ տ տ (8) Someit Sidhu տ տ տ (9) Parvinder Thiara տ տ տ Proposal 2. Ratification of our independent registered public accounting firm: To ratify, by ordinary resolution, the appointment by the Audit Committee of the Company’s Board of Directors of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 and until the next annual general meeting of shareholders to be held in 2025. FOR տ AGAINST տ ABSTAIN տ Proposal 3. Adjournment of the Annual Meeting: To approve, by ordinary resolution, the adjournment of the Annual Meeting by the chairman thereof to a later date, if necessary, for the purpose of soliciting additional proxies in favor of the foregoing proposals, in the event the Company does not receive the requisite shareholder votes to approve the foregoing proposals. FOR տ AGAINST տ ABSTAIN տ Note: Such other business that may properly come before the meeting. Date Signature Signature (Joint Owners) Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer. • PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. • PROXY VOTING INSTRUCTIONS Please have your 11-digit control number ready when voting by Internet or when voting during the Annual General Meeting. sig VIRTUAL CONTROL NUMBER

    Get the next $ZURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZURA

    DatePrice TargetRatingAnalyst
    2/9/2026$15.00Outperform
    Wedbush
    11/4/2024$15.00Outperform
    Leerink Partners
    9/5/2024$5.00Neutral
    H.C. Wainwright
    5/3/2024$26.00Overweight
    Piper Sandler
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    8/25/2023$17.00Outperform
    Oppenheimer
    6/22/2023$20.00Buy
    Guggenheim
    6/14/2023$14.00Buy
    Chardan Capital Markets
    More analyst ratings

    $ZURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its senior leadership team will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 11:00 AM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day. A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at lea

    2/4/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Business Updates and Outlook for 2026

    2026 begins as a transformative year for Zura with potential clinical validation of tibulizumab as a groundbreaking therapy in hidradenitis suppurativa (HS) Expanded Phase 2 TibuSHIELD trial in HS expected to deliver topline data in the fourth quarter of 2026 Zura maintains a strong financial position with cash expected to fund planned operations through 2027, beyond the data readouts in both HS and systemic sclerosis (SSc) Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported busine

    1/12/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Thiara Parvinder

    4 - Zura Bio Ltd (0001855644) (Issuer)

    1/27/26 6:45:33 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Thiara Parvinder

    3 - Zura Bio Ltd (0001855644) (Issuer)

    1/27/26 6:44:18 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Kulkarni Sandeep Chidambar

    4 - Zura Bio Ltd (0001855644) (Issuer)

    1/23/26 5:56:36 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ploos Van Amstel Arnout bought $496,000 worth of Class A ordinary shares (80,000 units at $6.20), increasing direct ownership by 400% to 100,000 units (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    5/23/24 8:53:36 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Howell Michael bought $24,999 worth of Class A ordinary shares (7,987 units at $3.13) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    4/24/24 6:54:25 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nistala Kiran bought $10,000 worth of Class A ordinary shares (3,195 units at $3.13) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    4/24/24 6:53:25 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Zura Bio Limited with a new price target

    Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    11/4/24 7:45:03 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Zura Bio Limited with a new price target

    H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00

    9/5/24 8:35:06 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    SEC Filings

    View All

    Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    2/11/26 6:02:43 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Leadership Update, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    1/23/26 6:21:39 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    1/12/26 6:45:55 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Financials

    Live finance-specific insights

    View All

    Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

    Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

    3/25/25 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

    Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria

    11/7/24 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

    Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress

    11/13/23 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Leadership Updates

    Live Leadership Updates

    View All

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Announces Chief Financial Officer Transition

    Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701021645/en/Eric Hyllengren Mr. Badial joined Zura Bio in March 2023, at the time of its business combination with

    7/1/25 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited

    8/13/24 9:21:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ZURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zura Bio Limited

    SC 13G - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 4:47:14 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care